Filing Details

Accession Number:
0000899243-22-009826
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-03-07 20:45:27
Reporting Period:
2022-03-03
Accepted Time:
2022-03-07 20:45:27
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1521036 Lantheus Holdings Inc. LNTH In Vitro & In Vivo Diagnostic Substances (2835) 352318913
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1754976 Jr. J. Robert Marshall C/O Lantheus Holdings, Inc.
331 Treble Cove Road
North Billerica MA 01862
Cfo And Treasurer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-03-03 25,911 $0.00 152,843 No 4 A Direct
Common Stock Disposition 2022-03-04 2,570 $49.98 150,273 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Acquisiton 2022-03-03 14,773 $0.00 14,773 $49.93
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
14,773 2032-03-03 No 4 A Direct
Footnotes
  1. Consists of 8,637 restricted stock units that vest in equal installments over a three-year period and 17,274 Total Shareholder Return performance-based restricted stock units ("PSUs") that cliff vest following a three-year performance period. The amount of PSUs included in this Report reflects the target award, however the ultimate award size can range from 0% to 200% of the target based on the actual performance achieved at the end of the performance period.
  2. The Company requires certain senior executives to cover tax liabilities resulting from the vesting of their equity awards pursuant to sell-to-cover transactions in compliance with Rule 10b5-1. The transaction reported in this Form 4 was effected in compliance with Rule 10b5-1 to satisfy withholding tax liabilities of the Reporting Person associated with the vesting of restricted stock previously granted and reported on a previously filed Form 4.
  3. The option vests in three equal annual installments beginning on March 3, 2023.